Efficacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean… (NCT03513250) | Clinical Trial Compass
CompletedNot Applicable
Efficacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean Section.
Egypt92 participantsStarted 2018-05-30
Plain-language summary
a prospective, randomized, placebo-controlled study will be conducted to investigate whether hyoscine-n-butylbromide has preventive effects on early postoperative CRBD in patients with urinary catheters who will undergo elective cesarean sections.
Who can participate
Age range18 Years – 40 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Elective primary or repeat cesarean section at or more than 38 weeks of gestation scheduled to insert a Foley catheter in the operation site.
Exclusion Criteria:
* • Urinary infection (assessed clinically and by urinalysis of midstream sample of urine (MSSU) with chemical indicator strips or dipsticks).
* Contraindications for general anesthesia.
* Maternal bladder, urethral and renal disorders causing irritating voiding problems such as dysuria, urge and stress incontinence.
* Obstructive voiding symptoms like incomplete emptying, straining and voiding difficulty before surgery.
* Overactive bladder (frequency: more than three times during the night or more than eight times in 24 h).
* Morbid obesity.
* Disturbances of the central nervous system (epilepsy, patients receiving MAO inhibitor).
* Hypertensive disorders and/ or systemic disease requiring particular patient care (for example, cardiac disease, nephritic disorders).
* Chronic analgesic abuse.
* Hepatic or psychiatric disease will be excluded from the study.
* A history of hypersensitivity or contraindication to hyoscine-n-butylbromide.
What they're measuring
1
catheter related bladder discomfort(CRBD) measured by numerical rating scale(NRS).